000			01627na a2200241 4500
999			_c94 _d94
003			H12O
005			20190820125256.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCastañeda Altamirano, Carlos _91790 _eOncología Médica
100			_aCiruelos Gil, Eva María _91082 _eOncología Médica
245	0	4	_aThe present and future of gene profiling in breast cancer. _h[artículo]
260			_bCancer Metastasis Reviews, _c2012
300			_a31(1-2):41-6.
500			_aFormato Vancouver: Espinosa E, Gámez-Pozo A, Sánchez-Navarro I, Pinto A, Castañeda CA, Ciruelos E, et al. The present and future of gene profiling in breast cancer. Cancer Metastasis Rev. 2012 Jun;31(1-2):41-6.
501			_aPMID: 22124734
504			_aContiene 47 referencias
520			_aGene signatures can provide prognostic and predictive information to help in the treatment of early-stage breast cancer. Although many of these signatures have been described, only a few have been properly validated. MammaPrint and OncoType offer prognostic information and identify low-risk patients who do not benefit from adjuvant chemotherapy. With regard to prediction of response, molecular subtypes of breast cancer differ in their sensitivity to chemotherapy, although further studies are needed in this field. Cost, small sample size, and the need to use central laboratories are common limitations to the widespread use of these tools.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/9/pc94.pdf _ySolicitar documento
942			_n0 _2ddc _cART